BRKR Quote, Financials, Valuation and Earnings

Avantor, Inc. has a net margin of -6.8% compared to Bruker Corp.'s net margin of -43.84%. Bruker Corp.'s return on equity of -1.2% beat Avantor, Inc.'s return on equity of -1.4%.

Bruker Corp. has a consensus price target of $54.43, signalling upside risk potential of 23.06%. On the other hand Avantor, Inc. has an analysts' consensus of $13.04 which suggests that it could grow by 20.59%. Given that Bruker Corp. has higher upside potential than Avantor, Inc., analysts believe Bruker Corp. is more attractive than Avantor, Inc..

Bruker Corp. has a beta of 1.169, which suggesting that the stock is 16.854% more volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.414%.

Bruker Corp. has a quarterly dividend of $0.05 per share corresponding to a yield of 0.45%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker Corp. pays 26.44% of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker Corp. quarterly revenues are $860.5M, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Bruker Corp.'s net income of -$58.5M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Bruker Corp.'s price-to-earnings ratio is 77.08x while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker Corp. is 1.95x versus 1.12x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Azenta, Inc. has a net margin of -6.8% compared to Bruker Corp.'s net margin of 32.45%. Bruker Corp.'s return on equity of -1.2% beat Azenta, Inc.'s return on equity of 1.44%.

Bruker Corp. has a consensus price target of $54.43, signalling upside risk potential of 23.06%. On the other hand Azenta, Inc. has an analysts' consensus of $43.50 which suggests that it could grow by 11.54%. Given that Bruker Corp. has higher upside potential than Azenta, Inc., analysts believe Bruker Corp. is more attractive than Azenta, Inc..

Bruker Corp. has a beta of 1.169, which suggesting that the stock is 16.854% more volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.316, suggesting its more volatile than the S&P 500 by 31.601%.

Bruker Corp. has a quarterly dividend of $0.05 per share corresponding to a yield of 0.45%. Azenta, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker Corp. pays 26.44% of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker Corp. quarterly revenues are $860.5M, which are larger than Azenta, Inc. quarterly revenues of $159.2M. Bruker Corp.'s net income of -$58.5M is lower than Azenta, Inc.'s net income of $51.7M. Notably, Bruker Corp.'s price-to-earnings ratio is 77.08x while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker Corp. is 1.95x versus 3.01x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of -6.8% compared to Bruker Corp.'s net margin of -5.98%. Bruker Corp.'s return on equity of -1.2% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Bruker Corp. has a consensus price target of $54.43, signalling upside risk potential of 23.06%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 272.72%. Given that Harvard Bioscience, Inc. has higher upside potential than Bruker Corp., analysts believe Harvard Bioscience, Inc. is more attractive than Bruker Corp..

Bruker Corp. has a beta of 1.169, which suggesting that the stock is 16.854% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.526, suggesting its more volatile than the S&P 500 by 52.562%.

Bruker Corp. has a quarterly dividend of $0.05 per share corresponding to a yield of 0.45%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker Corp. pays 26.44% of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker Corp. quarterly revenues are $860.5M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Bruker Corp.'s net income of -$58.5M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Bruker Corp.'s price-to-earnings ratio is 77.08x while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker Corp. is 1.95x versus 0.27x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of -6.8% compared to Bruker Corp.'s net margin of 6.76%. Bruker Corp.'s return on equity of -1.2% beat Revvity, Inc.'s return on equity of 3.05%.

Bruker Corp. has a consensus price target of $54.43, signalling upside risk potential of 23.06%. On the other hand Revvity, Inc. has an analysts' consensus of $116.19 which suggests that it could grow by 7.1%. Given that Bruker Corp. has higher upside potential than Revvity, Inc., analysts believe Bruker Corp. is more attractive than Revvity, Inc..

Bruker Corp. has a beta of 1.169, which suggesting that the stock is 16.854% more volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.054, suggesting its more volatile than the S&P 500 by 5.36%.

Bruker Corp. has a quarterly dividend of $0.05 per share corresponding to a yield of 0.45%. Revvity, Inc. offers a yield of 0.26% to investors and pays a quarterly dividend of $0.07 per share. Bruker Corp. pays 26.44% of its earnings as a dividend. Revvity, Inc. pays out 11.63% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker Corp. quarterly revenues are $860.5M, which are larger than Revvity, Inc. quarterly revenues of $698.9M. Bruker Corp.'s net income of -$58.5M is lower than Revvity, Inc.'s net income of $47.2M. Notably, Bruker Corp.'s price-to-earnings ratio is 77.08x while Revvity, Inc.'s PE ratio is 54.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker Corp. is 1.95x versus 4.58x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.